Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3714513 | 0.80 | PIK3CG (0.51) | PDE2AHPGDAPOBEC3AAPOBEC3GIRAK4 | |
| SCHEMBL19436832 | 0.79 | HPGD (0.46) | PDE2AHPGDAPOBEC3AAPOBEC3GIRAK4 | |
| SCHEMBL26172231 | 0.77 | HTR6 (0.53) | PDE2AHPGDAPOBEC3AAPOBEC3GALDH1A1 | |
| SCHEMBL16619547 | 0.76 | PIK3CG (0.45) | APOBEC3AAPOBEC3GSMPD3PIK3CGJAK2 | |
| SCHEMBL23728529 | 0.76 | APOBEC3A (0.45) | PDE2AHPGDAPOBEC3AAPOBEC3GALDH1A1 | |
| SCHEMBL31211823 | 0.76 | SMPD3 (0.46) | PDE2AHPGDAPOBEC3AAPOBEC3GSMPD3 | |
| SCHEMBL18208430 | 0.75 | PIK3CG (0.44) | APOBEC3AAPOBEC3GSMPD3PIK3CGJAK2 | |
| SCHEMBL7453195 | 0.74 | SMPD3 (0.43) | PDE2AHPGDSYKSMPD3IRAK4 | |
| SCHEMBL30630756 | 0.74 | ALDH1A1 (0.48) | IRAK4ALDH1A1LMNA | |
| SCHEMBL29987490 | 0.74 | PDE2A (0.42) | PDE2AHPGDAPOBEC3AAPOBEC3GALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PDE2A 3378/4885HPGD 3843/4885APOBEC3A 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.